炎症性肠病新型治疗方法的研究进展  

Recent Strides in Novel Treatments for Inflammatory Bowel Disease

作　　者：陈晓芬 陈钰涵 马娟[2] CHEN Xiaofen;CHEN Yuhan;MA Juan(Shantou University Medical College,Shantou 515041,China;Department of Gastroenterology,Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou 510080,China)

机构地区：[1]汕头大学医学院,广东省汕头市515041 [2]南方医科大学附属广东省人民医院、广东省医学科学院消化内科,广东省广州市510080

出　　处：《中国全科医学》2023年第27期3349-3354,共6页Chinese General Practice

基　　金：广州市科技计划项目(202102080007)。

摘　　要：炎症性肠病(IBD)是一组非特异性的慢性复发性肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病。IBD的病因和发病机制仍未被完全阐明,目前也尚无治愈方法。随着研究不断深入,肿瘤坏死因子α、白介素、整合素受体、Janus激酶(JAK)/STAT通路和肠道菌群等靶点在IBD的病理生理学过程中发挥的作用被逐渐揭示,并随之涌现出多种新型的治疗方法,如生物制剂及小分子药物、干细胞移植、粪菌移植、白细胞吸附等。虽然不少新型治疗方法仍在研究阶段,但已初步展现出良好的疗效和安全性,未来或许可以弥补既往治疗方案的不足,为IBD患者的个体化治疗提供更多的选择。本文就新型IBD治疗方法的最新研究进展进行阐述。Inflammatory bowel disease(IBD)is a chronic non-specific intestinal inflammatory disease featured by repetitive episodes of gastrointestinal inflammation,including ulcerative colitis and Crohn's disease.The etiology and pathogenesis of IBD have not been fully identified,and there is still no cure currently.Nevertheless,new treatments have been developed recently,such as biological agents and small-molecule drugs,stem cell transplantation,fecal bacteria transplantation,and monocyte adsorption apheresis,along with the roles of TNF-α,interleukin,integrin receptors,JAK/STAT pathway and intestinal flora in the pathophysiology of IBD gradually revealed by increasingly deepening research on IBD.Although many new treatments are still being researched,they have been proven effective and safe,which might make up for the shortcomings of previous therapies,and may be alternative choices for individualized treatment of IBD in the future.This article reviews the recent developments in novel treatments for IBD.

关 键 词：炎症性肠病 克罗恩病 溃疡性结肠炎 治疗 综述 

分 类 号：R574[医药卫生—消化系统]